同源康医药-B(02410):甲磺酸艾多替尼片(TY-9591片)的新药上市申请获国家药品监督管理局受理

智通财经
Feb 06

智通财经APP讯,同源康医药-B(02410)发布公告,本公司在研1类新药甲磺酸艾多替尼片(TY-9591片)的新药上市申请(NDA)被国家药品监督管理局(NMPA)药品审评中心(CDE)受理。

甲磺酸艾多替尼片(TY-9591片)为奥希替尼的氘代物,生物利用度高,入脑效果好,本次NDA注册申报适应症为具有EGFR外显子19缺失(19DEL)或外显子21(L858R)置换突变,并伴有CNS转移的局部晚期或转移性NSCLC成人患者的一线治疗。I期(TYKM1601101)和II期临床研究(TYKM1601201)数据已初步显示出其对NSCLC脑转移患者非常优异的颅内及全身应答率,临床获益明显,可解决未满足的临床需求,而关键II期临床研究(TYKM1601202)数据更进一步证实其优异疗效,并显示出其优于奥希替尼的颅内应答率和临床获益,甲磺酸艾多替尼片(TY-9591片)对治疗EGFR突变肺癌脑转移患者具有重大的临床价值。

甲磺酸艾多替尼片(TY-9591片)作为奥希替尼的氘代化合物,无论是从化学结构、药理作用、临床有效性和安全性、以及耐药机制分析,甲磺酸艾多替尼片(TY-9591片)都显示出更明显的临床价值和优势,对疾病的预后有明显改善作用。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10